<DOC>
	<DOCNO>NCT00952757</DOCNO>
	<brief_summary>Hyperprolactinaemia common side effect antipsychotic ( APS ) , include atypicals . Clinical consequence hyperprolactinaemia broad include amenorrhea , galactorrhea , tender breast , gynecomastia sexual dysfunction . Less know also present increase cardiovascular risk , specially woman , disorder osteoporotic type potential increase risk breast prostate cancer . Despite grow evidence , consistent publish data order adopt evidence-based decision may beneficial patient . This naturalistic observational 6 month follow-up study patient APS-induced hyperprolactinemia aim obtain information switch approach case hyperprolactinemia secondary APS well establish role switch quetiapine ( APS relate increase prolactin level ) problem .</brief_summary>
	<brief_title>Changes Hyperprolactinemia Secondary Antipsychotics After Switching Quetiapine</brief_title>
	<detailed_description>Hyperprolactinaemia common side effect antipsychotic ( APS ) , include atypicals . Clinical consequence hyperprolactinaemia include remarkably appearance amenorrhea , galactorrhea , tender breast , gynecomastia - associate dysmorphophobia psychological disorder case , particularly men- . Another common side effect sexual dysfunction , decrease libido , anorgasmia , men , impotence , reduce volume ejaculate even backward ejaculation . Less know also present increase cardiovascular risk , specially woman , disorder osteoporotic type . Furthermore , several author relate hyperprolactinemic state development breast cancer include potential bad prognosis ( Mandala , 1999 ; Clevenger 2003 ; Mujagic , 2004 ) , development metastatic prostate cancer resistance hormone therapy men ( Lisonni , 2005 ) Despite grow evidence fact APS apparent increase prolactin level exist , quetiapine aripiprazole , many clinicians n't even monitor prolactin level patient follow APS treatment . And , find consistent publish data order adopt evidence-based decision may beneficial patient . This naturalistic observational 6 month follow-up study patient APS-induced hyperprolactinemia aim obtain information switch approach case hyperprolactinemia secondary APS well establish role switch quetiapine problem .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Hyperprolactinemia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Informed consent signature . Men age 1850 year woman age 1845 year . Patients diagnose schizophrenia bipolar disorder accord DSMIV ambulatory psychiatric followup . Treated one antipsychotic quetiapine least 8 week prior inclusion study . Prolactin serum level 20 ug/L . That , opinion clinician , origin hyperprolactinemia antipsychotic treatment administer previously patient . Switching previous antipsychotic treatment quetiapine follow clinical criterion investigator response hyperprolactinemia period le 5 day prior inclusion study . Women childbearing potential use effective contraceptive method negative result pregnancy HCG test time inclusion . Be able understand meet study requirement . Pregnant nursing woman . Mental retardation . Dependence abuse substance inclusion accord DSMIV criterion . Patients , investigator 's opinion , high risk suicide mean risk aggression others . Treated follow drug modify PRL level inclusion study : antipsychotic , except quetiapine , antidepressant except mirtazapine , hormone therapy , spermicide , antiparkinson drug dopaminergic agonist , metoclopramide , domperidone , cimetidine ranitidine , verapamil , enalapril , alphamethyldopa , reserpine , morphine opioid derivative , antiretrovirals ( protease inhibitor ) , vitamin D complex contain . These drug exclude know potential effect prolactin serum level , sexual hormone and/or cortisol . Administration antipsychotic depot injection one usual administration interval depot ( e.g. , 34 week ) prior inclusion . Be treat follow P4503A4 cytochrome inhibitor 14 day prior inclusion , include : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , fluvoxamine , indinavir , nelfinavir , ritonavir saquinavir . Be treat follow P4503A4 cytochrome inducer 14 day prior inclusion , include : phenytoin , carbamazepine , barbiturate , rifampicin , St. John 's wart , glucocorticoid . Any contraindication use quetiapine fumarate investigator 's opinion ( include lack response previous treatment attempt ) ( applies also treatment use study comparative agent ) . Suffer medical condition effect absorption , distribution , metabolism excretion study treatment ( ) . Suffer medical condition decompensation receive inappropriate treatment investigator 's opinion ( e.g. , diabetes , angina pectoris , hypertension ... ) affect psychotic symptom and/or level prolactin , sexual hormone and/or cortisol . Suffering unstable diabetes . Absolute neutrophil count Â£1.5 x 109 per litre . Noncompliance study plan . Participation clinical trial four week prior inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>APS-related hyperprolactinaemia</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Bipolar</keyword>
</DOC>